Why carry out this study?

The launch of several new drugs in multiple sclerosis (MS) is expected in the near future, leading to concerns about sustainability for healthcare systems.

This study assessed expected changes in the MS landscape in Italy and their impact on expenditure by the Italian National Healthcare Service between 2023 and 2028.

What was learned from the study?

The number of equivalent MS patients treated in 2028 in Italy is estimated to increase by around 10% versus 2022.

First-line treatments currently in use are expected to progressively reduce their patient shares until 2028 in favor of treatments predominantly used as second line.

Despite the increase in the number of patients treated for MS and the launch of new innovative molecules, expenditure for MS is estimated to decrease from €721 million in 2022 to €551 million in 2028, mainly due to loss of exclusivity and renegotiation of drug prices.

The data collected to inform the model show long-term sustainability for the Italian National Healthcare Service and future availability of resources for new innovative treatment options.